Maxim Group Reiterates Bullish Stance on Strive (ASST), Sees 50% Upside to $1.50 Target
NEW YORK – Strive Inc. (NASDAQ: ASST), a company rapidly carving a niche at the intersection of digital asset management and healthcare technology, received a renewed vote of confidence from Wall Street this week. Analyst firm Maxim Group reiterated its Buy rating on the stock, maintaining a price target of $1.50, which implies a significant upside from recent trading levels.
The reaffirmation comes on the heels of Strive's strategic acquisition of Semler Scientific, finalized on January 16. The deal is a game-changer, instantly propelling Strive into the ranks of the world's top corporate Bitcoin holders. Semler's treasury, holding approximately 12,797.9 BTC, now forms a core part of Strive's assets, solidifying its stated mission as a premier Bitcoin treasury management firm. Beyond crypto, the acquisition brings Semler's portfolio of early disease detection technologies under Strive's umbrella.
"This isn't just a financial engineering play," said a market strategist familiar with the deal. "Strive is executing a deliberate two-pronged strategy: building a robust, Bitcoin-backed balance sheet while simultaneously acquiring revenue-generating healthcare tech assets. The appointment of former board member Avik Roy as Chief Strategy Officer to lead the monetization of Semler's business underscores that operational focus."
The move caps a transformative period for Strive. In the third quarter of 2025, the company went public via a reverse merger with Asset Entities Inc., raising over $762 million in the process and branding itself as the first publicly-traded firm of its kind. The Semler agreement was initiated during this phase, signaling an aggressive growth trajectory.
Strive operates through its main entity and a wholly-owned subsidiary, Strive Asset Management LLC, a private investment manager. The company's unique model—blending cryptocurrency treasury management with traditional subsidiary operations—places it in a distinctive, albeit complex, market position.
Market Voices: A Divided Street
Michael R., Portfolio Manager: "Maxim's call is logical. The $1.50 target reflects the embedded value of the Bitcoin treasury alone, essentially getting the healthcare tech and management platform for free at current prices. It's a high-risk, high-potential-reward situation typical of this market segment."
David Chen, Fintech Analyst: "The synergy is speculative but intriguing. Can they effectively leverage Semler's cash flows to support or expand the Bitcoin strategy? Can the 'Bitcoin treasury' narrative attract a premium valuation? Execution risk is high, but the blueprint is unique."
Sarah J., Independent Trader (Sharply Critical): "This is a Frankenstein stock—a reverse merger, a PIPE financing, a Bitcoin hype grab, and now a medical tech company slapped on top. It reeks of financial engineering over substance. Calling it a 'premier' anything is a joke. Retail investors chasing this are being sold a story, not a business."
Arun Patel, Venture Capitalist: "Love it or hate it, Strive is testing a new corporate model. In a climate where treasury diversification is key, holding a substantial Bitcoin position is a bold statement. The success hinges entirely on Roy's team's ability to grow Semler's core business profitably."